Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study
Titel:
Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study
Auteur:
Schmid, P. Salgado, R. Park, Y.H. Muñoz-Couselo, E. Kim, S.B. Sohn, J. Im, S.-A. Foukakis, T. Kuemmel, S. Dent, R. Yin, L. Wang, A. Tryfonidis, K. Karantza, V. Cortés, J. Loi, S.